Abbisko Cayman Limited

DB:8ZD Stock Report

Market Cap: €856.1m

Abbisko Cayman Valuation

Is 8ZD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 8ZD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 8ZD (€1.18) is trading below our estimate of future cash flow value (€3.15)

Significantly Below Future Cash Flow Value: 8ZD is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 8ZD?

Key metric: As 8ZD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 8ZD. This is calculated by dividing 8ZD's market cap by their current earnings.
What is 8ZD's PE Ratio?
PE Ratio119.4x
EarningsCN¥55.25m
Market CapCN¥6.59b

Price to Earnings Ratio vs Peers

How does 8ZD's PE Ratio compare to its peers?

The above table shows the PE ratio for 8ZD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average47.6x
2INV 2invest
2.4xn/a€62.9m
7V0 Novogenia
147.4x64.28%€80.4m
2INV 2invest
13.1xn/a€45.1m
2157 Lepu Biopharma
27.3xn/aHK$8.3b
8ZD Abbisko Cayman
119.4x-77.48%€7.6b

Price-To-Earnings vs Peers: 8ZD is expensive based on its Price-To-Earnings Ratio (119.4x) compared to the peer average (47.6x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does 8ZD's PE Ratio compare vs other companies in the European Biotechs Industry?

8 CompaniesPrice / EarningsEstimated GrowthMarket Cap
8ZD 119.4xIndustry Avg. 16.6xNo. of Companies8PE020406080100+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 8ZD is expensive based on its Price-To-Earnings Ratio (119.4x) compared to the European Biotechs industry average (16.6x).

Price to Earnings Ratio vs Fair Ratio

What is 8ZD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

8ZD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio119.4x
Fair PE Ratio3.6x

Price-To-Earnings vs Fair Ratio: 8ZD is expensive based on its Price-To-Earnings Ratio (119.4x) compared to the estimated Fair Price-To-Earnings Ratio (3.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 8ZD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.18
€2.42
+104.95%
12.51%€2.80€1.95n/a6
Jul ’27€1.19
€2.54
+113.08%
8.84%€2.81€2.23n/a6
Jun ’27€1.03
€2.52
+144.34%
7.82%€2.81€2.24n/a7
May ’27€1.40
€2.52
+79.69%
7.63%€2.77€2.21n/a8
Apr ’27€1.40
€2.65
+89.07%
14.96%€3.70€2.21n/a10
Mar ’27€1.30
€2.58
+98.28%
16.30%€3.62€1.99n/a11
Feb ’27€1.27
€2.61
+105.44%
17.00%€3.65€2.01n/a11
Jan ’27€1.37
€2.58
+88.29%
16.93%€3.59€1.98n/a11
Dec ’26€1.54
€2.60
+68.89%
17.24%€3.62€2.00n/a11
Nov ’26€1.57
€2.56
+62.87%
18.02%€3.59€1.98n/a10
Oct ’26€1.86
€2.20
+18.20%
16.92%€2.73€1.58n/a7
Sep ’26€1.84
€1.66
-9.65%
22.29%€1.97€0.91n/a6
Aug ’26€1.10
€1.44
+31.05%
24.12%€1.95€0.90n/a7
Jul ’26€1.05
€1.32
+25.32%
27.62%€2.09€0.96€1.197
Jun ’26€1.05
€1.32
+25.32%
27.62%€2.09€0.96€1.037
May ’26€0.83
€1.31
+56.53%
29.73%€2.14€0.98€1.406
Apr ’26€0.98
€1.31
+33.37%
29.73%€2.14€0.98€1.406
Mar ’26€0.70
€1.13
+60.83%
58.66%€2.23€0.44€1.304
Feb ’26€0.57
€1.12
+96.60%
58.32%€2.19€0.44€1.274
Jan ’26€0.53
€1.12
+113.46%
58.32%€2.19€0.44€1.374
Dec ’25€0.54
€1.12
+108.43%
58.43%€2.18€0.44€1.544
Nov ’25€0.51
€1.04
+103.34%
59.99%€1.89€0.43€1.573
Oct ’25€0.42
€1.04
+144.59%
59.99%€1.89€0.43€1.863
Sep ’25€0.33
€1.04
+212.37%
59.99%€1.89€0.43€1.843
Aug ’25€0.32
€1.04
+220.08%
59.99%€1.89€0.43€1.103
Jul ’25€0.37
€1.04
+182.54%
59.70%€1.89€0.43€1.053
€2.4
Fair Value
50.8% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/23 06:01
End of Day Share Price 2026/07/23 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Abbisko Cayman Limited is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ziyu HeChina International Capital Corporation Limited
null nullChina International Capital Corporation Limited
Jin ZhangChina International Capital Corporation Limited